HeartBeam Q2 loss widens despite clinical progress

HeartBeam Inc. reported a wider net loss for the second quarter despite progress in its clinical development pipeline, according to slides released on Tuesday.

The cardiac monitoring company’s Q2 net loss deepened to $10.2 million from $7.8 million in the same period last year, exceeding analyst expectations. Revenue fell 18% year-over-year to $1.1 million, reflecting continued challenges in commercialization amid a competitive medical device market.

Despite the financial headwinds, HeartBeam emphasized advancements in its clinical trials, including positive interim data from its pivotal study evaluating its AI-driven cardiac monitoring system. The company stated that the trial remains on track for completion by year-end, with interim results showing improved diagnostic accuracy compared to traditional methods.

HeartBeam’s management attributed the widening loss to higher research and development spending, regulatory compliance costs, and lower-than-anticipated product sales. The firm reiterated its long-term strategy to secure FDA clearance and commercialize its technology, though no timeline for profitability was provided.

Analysts noted that while the clinical progress is encouraging, the path to market adoption remains uncertain given the company’s financial constraints and competitive pressures in the cardiac monitoring sector.

HeartBeam’s shares were down 3% in after-hours trading following the release of the slides.

The company did not immediately respond to requests for additional comment.